Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAI.0000000000002098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics.
Expert Rev Pharmacoecon Outcomes Res
January 2025
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Background: Empirical evidence regarding temporal trends in cost per quality-adjusted life year (QALY) gained remains limited. This study investigates the evolution of cost-effectiveness for diabetes mellitus treatments over time.
Research Design And Methods: We analyzed cost-effectiveness analyses of anti-diabetic pharmaceuticals extracted from the Tufts Medical Center Cost-Effectiveness Analysis Registry (CEAR).
Resilience in Medical Education: Examining the Effects of the COVID-19 Pandemic on Pre-clerkship Curriculum Outcomes and Learner Perceptions at the University of Hawai'i John A. Burns School of Medicine.
Hawaii J Health Soc Welf
January 2025
Office of Medical Education, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI (SFTF).
The transition to virtual learning formats during the COVID-19 pandemic necessitated substantial curricular adjustments to the University of Hawai'i John A. Burns School of Medicine. This study compares student satisfaction and academic performance between the pre-pandemic (up through March 25, 2020) and pandemic (after March 25, 2020) periods.
View Article and Find Full Text PDFInterrupted-time-series analysis of the impact of COVID-19 pandemic on blood culture utilization in Shanghai.
BMC Infect Dis
January 2025
Department of Disease Prevention and Control, Second Affiliated Hospital of Navy Medical University, Shanghai, China.
Background: Limited information is available regarding the changes in blood culture utilization following the COVID-19 pandemic. Blood culture utilization rate is a critical indicator of diagnostic efficiency for infectious diseases. This study aims to describe the impact of the COVID-19 pandemic on blood culture utilization rate in Shanghai.
View Article and Find Full Text PDFTechnological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
World J Urol
January 2025
Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
Purpose: The purpose of this study was to investigate the efficacy of Transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology in the treatment of benign prostatic hyperplasia (BPH), with a focus on preserving sexual function postoperatively.
Methods: Conducted as a multicenter, prospective, single-blind randomized controlled trial, this study enrolled sexually active male patients with BPH. Participants were randomized into three groups: standard HoLEP (Group A), single-n technology (Group B), and innovative double-n technology (Group C), which emphasizes the preservation of the urethral mucosa and nearby structures.
Trends in global and regional incidence and prevalence of hypertensive disordersin pregnancy (1990-2021): an age-period-cohort analysis.
Sci Rep
January 2025
Department of Gynecology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, Ningxia, China.
Hypertensive disorders of pregnancy (HDP) are significant global health issues. This study utilized data from the Global Burden of Disease Study 2021 to analyze trends in incidence, prevalence, and Disability-Adjusted Life Years (DALY) associated with HDP across 204 countries from 1990 to 2021. The analysis employed estimated annual percentage changes and an age-period-cohort model, stratifying data by age, year, geographical region, and sociodemographic index (SDI).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!